Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "CRISPR"


25 mentions found


CNN —Scientists have grown kidneys containing mostly human cells inside pig embryos, an important step toward growing kidneys and potentially other human organs that could be used for transplants in people. “The paper describes pioneering steps in a new approach to organ bioengineering using pigs as incubators for growing and cultivating human organs,” said Dusko Ilic, a professor of stem cell sciences at King’s College London, in a statement. “It is remarkable to see about 60% of the primordial pig kidney contained human cells,” Wu said. What the researchers didTo generate kidneys mostly composed of human cells in pigs, the scientists used cutting-edge techniques harnessing advances in stem cells, gene editing and embryology. “This (new) work is different from existing xenotransplantation approach and aims to generate organs mostly composed of human cells in pigs,” Wu said.
Persons: , Miguel Esteban, ” Esteban, , Dusko Ilic, Jun Wu, Wu, ” Mary Garry, ” Wu, Esteban, ” Joseph A, Vassalotti, ” Vassalotti Organizations: CNN —, Guangzhou Institute of Biomedicine, Chinese Academy of Sciences, Procurement, Transplantation Network, King’s College London, University of Texas Southwestern Medical Center, University of Minnesota’s, Heart Institute, National Kidney Foundation, Icahn School of Medicine Locations: Health, United States, Mount Sinai
(Reuters) - U.S. law firm Paul Hastings said Thursday that it has hired two partners from rival Goodwin Procter as practice leaders in New York and Washington, D.C.Seo Salimi is departing Goodwin after more than eight years to co-lead Paul Hastings' equity capital markets and corporate life sciences practices in New York. His clients have included Karuna Therapeutics, CRISPR Therapeutics, Goldman Sachs and J.P. Morgan Securities, according to his former profile on Goodwin's website. Salimi is joining Paul Hastings along with Sean Donahue, who will chair the firm's public company advisory practice group and co-chair its shareholder activism and takeover defense group. The Los Angeles-founded firm has hired at least 24 partners globally since January. Read more:Law firm Goodwin taps new Silicon Valley-based chairPaul Hastings team takes Latin America-focused deal practice to Baker McKenzieOur Standards: The Thomson Reuters Trust Principles.
Persons: Paul Hastings, Goodwin Procter, Seo Salimi, Goodwin, Salimi, Goldman Sachs, J.P, Sean Donahue, Donahue, Dana Syracuse, Perkins Coie, Kenneth Deutsch, Latham & Watkins, Baker McKenzie Organizations: Reuters, . Securities, Exchange Commission, Karuna Therapeutics, CRISPR Therapeutics, Morgan Securities, Washington , D.C, of Corporation Finance, Latham &, Latin, Thomson Locations: New York, Washington, Washington ,, SEC's, Los Angeles, Boston, Latin America
Pfizer makes equity investment in Caribou Biosciences
  + stars: | 2023-07-06 | by ( ) www.reuters.com   time to read: +2 min
July 6 (Reuters) - Pfizer (PFE.N) has invested $25 million to buy a minority stake in Caribou Biosciences (CRBU.O), making it the latest small biotechnology firm to attract the pharmaceutical giant's interest. The news lifted shares of Caribou more than 61% in early trade. Pfizer purchased nearly 4.7 million Caribou shares at $5.33 per share, Caribou said on Thursday, representing a premium of about 30% over Caribou's previous close price. This represents 7.64% of outstanding shares in Caribou, according to Reuters' calculation based on Refinitiv IBES data. It also made a $25 million equity investment in Akero Therapeutics (AKRO.O) last year.
Persons: Caribou, NASH, Jennifer Doudna, Raghav Mahobe, Leroy Leo, Maju Samuel Organizations: Pfizer, Caribou Biosciences, Biohaven Pharmaceutical, Akero Therapeutics, Thomson Locations: Caribou, California, Bengaluru
Authorities in China took multiple steps to tighten rules and ethical standards affecting human gene editing in the wake of the revelations about his previous research. But the scientist’s release of a new proposal involving gene editing of embryos has scientists and medical ethics experts concerned – and confused. Genetic manipulation of human embryos – both viable and nonviable ones – is typically tightly controlled globally and some countries ban all such research, experts say. But there is robust global debate around allowing genome editing of human embryos to treat serious genetic conditions or expanding research. Chinese law does not allow gene-edited human embryos used in research to be implanted into humans, or developed for more than 14 days.
Persons: , It’s, Peter Dröge, , “ I’m, ” Joy Zhang, bioethicists, There’s, He’s, He’s “, Françoise Baylis, ” Baylis Organizations: Hong Kong CNN, Authorities, Nanyang Technological University, Centre for Global Science, University of Kent, CNN, bioethicists, Twitter, China’s Ministry of Science, Technology, National Health Commission, Southern University of Science, China’s biosciences, Dalhousie University Locations: Hong Kong, China, Beijing, Singapore, Britain, USA, Europe, Shenzhen
In 2017, Walt Disney World unveiled an animatronic of then-President Donald Trump. It just looks wrong in a way that doesn't make any sense to my brain," Goldman told Insider. Goldman said the appeal of the Clinton-Trump animatronic conspiracy lies partially in its harmlessness but also its humor. I don't imagine that there's much more that people are willing to tell, but who knows," Goldman told Insider. Walt Disney World and Disney Imagineers did not immediately respond to Insider's request for comment.
Persons: Donald Trump, Hillary Clinton, , Trump, Clinton, Alex Goldman, Disney, Goldman, it's, Hillary, Imagineer, Ellen DeGeneres animatronics, he's, Ellen DeGeneres, Disney Imagineers Organizations: Walt Disney World, Service, Walt Disney, Presidents, Disney, Twitter, Trump, Hall, Clinton, Star Wars Locations: Orlando, Epcot, Pirates, Caribbean
Some of this work is done by Britain's' Cambridge University, South Korea's Bundang CHA Hospital, International Stem Cell Corp's (ISCO.PK) Cyto Therapeutics in Australia, the Chinese Academy of Sciences, Harvard University and Japan's Kyoto University Hospital. For BlueRock's experimental therapy, researchers took induced pluripotent stem cells, which are modified to regain the ability to form any type of specialised tissue, and transformed them into dopamine-producing nerve cells. When surgically implanted into the brain of a person with Parkinson's disease, the therapeutic cells are designed to restore neural networks destroyed by the disease. Initial trial results showed the cells multiplied and started making dopamine, an important brain signalling molecule which is lacking in Parkinson's patients. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.
Persons: Wolfgang Rattay, Bayer, BlueRock, Britain's, Jennifer Doudna, Ludwig Burger, Miranda Murray, Mark Potter Organizations: Bayer AG, REUTERS, Bayer, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, BlueRock Therapeutics, Mammoth Biosciences, Thomson Locations: Leverkusen, Germany, FRANKFURT, Australia, San Francisco Bay
Hype springs eternal in medicine, but lately the horizon of new possibility seems almost blindingly bright. “I’ve been running my research lab for almost 30 years,” says Jennifer Doudna, a biochemist at the University of California, Berkeley. And yet these brutal years — which brought more than a million American deaths and probably 20 million deaths worldwide, and seemed to return even the hypermodern citadels of the wealthy West to something like the experience of premodern plague — might also represent an unprecedented watershed of medical innovation. “It’s stunning,” says the immunologist Barney Graham, the former deputy director of the Vaccine Research Center and a central figure in the development of mRNA vaccines, who has lately been writing about a “new era for vaccinology.” “You cannot imagine what you’re going to see over the next 30 years. The pace of advancement is in an exponential phase right now.”
Persons: I’ve, , Jennifer Doudna, Doudna, Barney Graham Organizations: University of California, Army, Vaccine Research Center Locations: Berkeley, West
Death cap mushrooms kill up to 100 people per year and sicken thousands more but have no antidote. Scientists used CRISPR to help identify a chemical that could become the first death cap antidote. A recent study in Nature Communications finally found a possible death cap mushroom antidote. A death cap mushroom antidote is long-awaitedMushroom foragers can easily mistake death cap mushrooms for other edible fungi. When the researchers tested ICG in mice poisoned with the death cap mushroom toxin, the results were eye-opening.
Sometimes there’s not enough rain when seedlings need water, or too much when the plants need to keep their heads above water. Rice farmers are shifting their planting calendars. On top of that, there’s climate change: It has upended the rhythm of sunshine and rain that rice depends on. That’s a fraction of the emissions from coal, oil and gas, which together account for 35 percent of methane emissions. His experiment, carried out over seven years, concluded that by not flooding the fields continuously, farmers can reduce rice methane emissions by more than 60 percent.
As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. "Valuation multiples across disease areas show CNS [ or central nervous system] and Genetic Medicine at relative low points." In July, the Food and Drug Administration could grant full approval to Leqembi , its Alzheimer's Disease treatment. As a very new area of medicine, gene therapy has greatest potential to accelerate sales growth as treatments come to market. He described immunology multiples as "generally stable" and genetic medicine multiples as highly volatile.
Final Trades: Berkshire, Devon Energy & CRISPR Therapeutics
  + stars: | 2023-05-09 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Berkshire, Devon Energy & CRISPR TherapeuticsThe "Halftime Report" traders give their top picks to watch for the second half.
If successful, Amgen would claim ownership of all antibodies that inhibit the PCSK9 protein, the mechanism of action for both Repatha and Praluent. Other companies could then do the same with their own antibody treatments in other disease areas. The case might also affect newer technologies used in medicine, such as CRISPR gene editing and messenger RNA, she said. A Washington, D.C.-based federal appeals court that covers U.S. patent cases invalidated Amgen's patent claiming ownership of all PCSK9 inhibitors as a whole in 2021. Amgen sued Sanofi and Regeneron in 2014.
How GSK plans to replenish its depleted medicine cabinet
  + stars: | 2023-03-15 | by ( Maggie Fick | ) www.reuters.com   time to read: +6 min
GSK has since suffered a series of clinical trial setbacks in its cancer drugs portfolio, most recently last year involving ovarian cancer drug Zejula and blood cancer drug Blenrep. BLOCKBUSTER POTENTIALAnalysts say that despite a string of strong quarterly earnings, lingering concerns over the company's drug pipeline reflect in GSK's share price. The investor said he does not see enough GSK drugs, either on the market or in development, with potential to be a so-called "blockbusters" with annual sales exceeding $1 billion. But Wood said the overhauled R&D department has put GSK in a strong position to meet growth targets. U.S. regulatory approval on GSK's vaccine, and a rival vaccine developed by Pfizer, is expected in May.
Shares of biotech company bluebird bio should double in the coming year, thanks to its treatments for sickle cell disease, a genetic blood disease and a rare genetic brain condition, according to Baird. The Wall Street firm initiated coverage of the stock on Monday with an outperform rating and $10 price target, which implies 104% upside from Monday's close. The company's management said in January that 40 patients had initiated benefits verification for Zynteglo during the last three months of 2022. Lastly, Baird expects the use of bluebird's Skysona treatment for CALD, which was approved in September 2022, to increase significantly in the coming years. The under-the-radar stock, which has a market cap of over $500 million, is down about 29% this year, as of Monday's close.
Feng Zhang, Aera's founder and a CRISPR pioneer, spoke with Insider about his vision for the firm. Aera wants to "break open the barrier" of tech through methods like gene editing, Zhang said. The CRISPR pioneer Feng Zhang spoke with Insider about Aera Therapeutics, his Boston-based biotech. "The goal is to break open the barrier that's facing genetic medicine," Zhang told Insider in his first interview about the company. In starting another company, Zhang said he felt it was important to have a dedicated team focused on delivery.
The gene-editing startup Aera has hired biotech vets Akin Akinc as CEO and John Maraganore as chairman. CRISPR pioneer Feng Zhang's newest gene-editing venture has attracted two longtime leaders of the biotech giant Alnylam Pharmaceuticals, Insider has learned. Former Alnylam CEO John Maraganore is chairman of Aera. The SEND technology could allow gene-editing technology to treat more diseases. Based on Zhang's SEND research, Aera hopes to deliver gene-editing tools to more organs, ultimately expanding the number of diseases CRISPR can impact.
Cathie Wood just scored her best month ever as her innovation stocks staged a big comeback, and some of her darlings still have double-digit upside ahead, according to Wall Street analysts. Wood's flagship Ark Innovation ETF (ARKK) jumped 27.8% in January alone, notching its strongest month since its inception in 2014 . We looked at companies with at least five analysts covering them, and these names below all have more than 10% upside in the next 12 months, according to FactSet. Wall Street analysts are most bullish on Ginkgo Bioworks , seeing the stock rally more than 140% in the next 12 months. Other biotech names in the space that analysts love are Verve Therapeutics , CRISPR Therapeutics , Beam Therapeutics and Twist Bioscience.
Scientists at Auburn University injected alligator DNA into farm-raised catfish. They hope the new and less disease-prone catfish will one day be sold for human consumption. A group of scientists at Auburn University published a paper in January detailing their efforts to genetically modify catfish with the cathelicidin gene of an alligator. The gene, which was added using CRISPR, heightened disease resistance among the catfish in comparison to wild catfish. However, researchers hope that the alligator and catfish gene-editing can be used in tandem with other catfish breeding techniques to help farmers with their catfish yields.
Loading chart...Qualtrics International Inc : "I really like XM as a long-term growth play. ... Let these guys do their work and then it's a buy." Loading chart...Clearfield Inc : "There's an analyst that cut numbers and the stock fell apart. That was ridiculous." Loading chart...CRISPR Therapeutics AG : "That's one of those crazy science stocks that in this market will work perfectly."
Activist Commentary: Inclusive Capital Partners is a San Francisco-based investment firm focused on increasing shareholder value and promoting sound environmental, social and governance practices. As a pioneering active ESG ("AESG") investor, Inclusive seeks long-term shareholder value through active partnership with companies whose core businesses contribute solutions to this pursuit. Bayer's crop science division accounts for approximately 25% of global crop farming. There are several ways to create this shareholder value. Bayer currently trades at approximately 7x earnings while its pure-play crop science peer, Corteva, trades at closer to 20x earnings.
The biotech halted the trial while it investigates the case, which may impact other CRISPR companies. The small biotech company Graphite Bio said Thursday afternoon that it paused a study testing an experimental gene-editing therapy after the first treated patient suffered a serious side effect. The safety scare raises more questions than answers as Graphite's scientists investigate what exactly may have caused the side effect. Lehrer said it's too early to say whether this safety scare could have implications for the broader gene-editing field. Its next-closest product, a gene-editing therapy for beta-thalassemia, isn't expected to start initial human testing until 2024 at the earliest.
A 13-year-old girl was the world's first patient to get a cell therapy called base editing in May. Base editing is a new gene-editing technology that could lead to cures for many diseases. Alyssa, 13, was the first-ever patient to receive a base-edited cell therapy after enrolling in a clinical trial in May. Base editing allows scientists to make ultraprecise changes to single letters of DNA in cells. Alyssa, a teenager in Leicester, England, received a base-edited cell therapy to treat her leukemia.
"We are the Underground Railroad of 'Gattaca' babies and people who want to do genetic stuff with their kids," Malcolm told me. Ellison, meanwhile, who has two children in their 30s, has reportedly resumed having kids — with his 31-year-old girlfriend. "The person of this subculture really sees the pathway to immortality as being through having children," Simone said. The person of this subculture really sees the pathway to immortality as being through having children. Before she met Malcolm, Simone was convinced she wanted to live her life single and child-free.
Will we cover 75% of California with green energy tech? Given these existing technological limitations and regulations, the aggregate demand for land to power our future green economy is huge. We would need 120,000 square miles, or 77 million acres, of land to install the wind and solar facilities for the energy transition. As cities expand, rising land prices in these areas would further constrain the location options for green energy generators. The political backlash in rural America could be alleviated if the economic gains from green power are large enough.
A decade ago, CAR T cell therapy changed the world of cancer treatment, offering a personalized approach to patients with blood cancers like leukemia. A novel approach to CAR T (chimeric antigen receptor T cell) therapy aims to cut down that turnaround time significantly. Instead of reprogramming each patient's cells, researchers are testing the safety of using universal, or "off the shelf," CAR T cells from other patients, preprogrammed to fight cancer. Scientists at University College London in the United Kingdom tested the safety of the experimental approach in six children — mostly toddlers — with advanced leukemia. One particular side effect associated with CAR T therapy is called a cytokine storm, and it can be deadly.
Total: 25